US2012083035A1PendingUtilityA1

Modified Cell Lines for Increasing Lentiviral Titers

37
Assignee: SPAYD KATIE JANSENPriority: Sep 30, 2010Filed: Aug 31, 2011Published: Apr 5, 2012
Est. expirySep 30, 2030(~4.2 yrs left)· nominal 20-yr term from priority
Inventors:Katie Jansen SpaydJon KarpilowJohn K. Wakefield
C12N 2740/15051C12N 15/86C12N 2740/15052C12N 15/113
37
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure provides a method of modifying cells in order to enhance lentiviral titers, cell lines that are modified and modifying reagents. By mediating individual genes and combination thereof, lentiviral titers may be increased.

Claims

exact text as granted — not AI-modified
1 . A method of enhancing lentiviral titers comprising modulating expression of a plurality of host genes in a packaging cell. 
     
     
         2 . The method of  claim 1  wherein the genes are selected from the group consisting of Annexin2, Tsg101, DBR1, RNA Helicase A, SOCS1, and TRBP, Dicer, Drosha, DGCR8, Hrs, Tetherin, CDK13, TRIM-5alpha, PRMT6, miR-29a, miR-29b, and miR-29c. 
     
     
         3 . The method of  claim 2 , wherein the cell is an HEK-293 cell. 
     
     
         4 . The method of  claim 2 , wherein the cell is an HEK-293T cell. 
     
     
         5 . The method of  claim 2 , wherein the plurality of host gene comprises and DGCR8 and either Hrs or Tetherin. 
     
     
         6 . The method of  claim 2 , wherein the plurality of host genes comprises DGCR8 and Tsg101. 
     
     
         7 . The method of  claim 2 , wherein the plurality of host genes comprises DGCR8 and Annexin2. 
     
     
         8 . The method of  claim 2 , wherein the plurality of host genes comprises Hrs and Tetherin. 
     
     
         9 . The method of  claim 2 , wherein the plurality of host genes comprises Hrs and Annexin 2. 
     
     
         10 . The method of  claim 2 , wherein the plurality of host genes comprises Tetherin and Tsg101. 
     
     
         11 . The method of  claim 2 , wherein the plurality of host genes comprises Tetherin and Annexin2. 
     
     
         12 . The method of  claim 2 , wherein the plurality of host genes comprises Tsg and Annexin 2. 
     
     
         13 . The method of  claim 2 , wherein the plurality of host genes comprises DGCR8, Hrs and Tetherin. 
     
     
         14 . The method of  claim 2 , wherein the plurality of host genes comprises DGCR8, Hrs and Annexin 2.

Join the waitlist — get patent alerts

Track US2012083035A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.